Effects of adenosine agents on apomorphine-induced yawning in rats. 1995

M R Zarrindast, and F Fatehi, and M Mohagheghi-Badi
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Iran.

In the present work, adenosine agonists and antagonists on apomorphine-induced yawning in rats was investigated. Subcutaneous (SC) injection of apomorphine (0.02, 0.05 and 0.1 mg/kg) induced dose-dependent yawning behaviour in rats. Intracerebroventricular (ICV) administration of different doses of the drug (1, 3, 5 micrograms/rat) also caused a dose-related yawning. ICV administration of the adenosine receptor agonists 5-N-ethylcarboxamidoadenosine (NECA) and N6-cyclohexyladenosine (CHA) decreased apomorphine-induced yawning. The response induced by the adenosine agonists was reduced by 8-phenyladenosine (8-PT) pretreatment. The yawning induced by SC and ICV administration of apomorphine was decreased by ICV or IP injection of theophylline, respectively. It is concluded that at least A1 adenosine receptors may exert negative influence on the apomorphine-induced yawning. However, the exact mechanism(s) of adenosine receptors in this behaviour remain to be established.

UI MeSH Term Description Entries
D008297 Male Males
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D000241 Adenosine A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Adenocard,Adenoscan
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001058 Apomorphine A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use. Apokinon,Apomorphin-Teclapharm,Apomorphine Chloride,Apomorphine Hydrochloride,Apomorphine Hydrochloride Anhydrous,Apomorphine Hydrochloride, Anhydrous,Apomorphine Hydrochloride, Hemihydrate,Britaject,Apomorphin Teclapharm
D015000 Yawning An involuntary deep INHALATION with the MOUTH open, often accompanied by the act of stretching. Yawnings
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D058906 Purinergic P1 Receptor Agonists Compounds that bind to and stimulate PURINERGIC P1 RECEPTORS. Adenosine Receptor Agonists,P1 Purinoceptor Agonists,Agonists, Adenosine Receptor,Agonists, P1 Purinoceptor,Purinoceptor Agonists, P1,Receptor Agonists, Adenosine
D058915 Purinergic P1 Receptor Antagonists Compounds that bind to and block the stimulation of PURINERGIC P1 RECEPTORS. Adenosine Receptor Antagonist,P1 Purinoceptor Antagonist,Purinergic P1 Receptor Antagonist,Adenosine Receptor Antagonists,P1 Purinoceptor Antagonists,Antagonist, Adenosine Receptor,Antagonist, P1 Purinoceptor,Antagonists, Adenosine Receptor,Antagonists, P1 Purinoceptor,Purinoceptor Antagonist, P1,Purinoceptor Antagonists, P1,Receptor Antagonist, Adenosine,Receptor Antagonists, Adenosine

Related Publications

M R Zarrindast, and F Fatehi, and M Mohagheghi-Badi
September 1981, Behavioral and neural biology,
M R Zarrindast, and F Fatehi, and M Mohagheghi-Badi
September 1984, European journal of pharmacology,
M R Zarrindast, and F Fatehi, and M Mohagheghi-Badi
September 1995, General pharmacology,
M R Zarrindast, and F Fatehi, and M Mohagheghi-Badi
September 1998, European journal of pharmacology,
M R Zarrindast, and F Fatehi, and M Mohagheghi-Badi
December 1995, General pharmacology,
M R Zarrindast, and F Fatehi, and M Mohagheghi-Badi
January 1984, Neuropharmacology,
M R Zarrindast, and F Fatehi, and M Mohagheghi-Badi
August 2000, Pharmacology & toxicology,
M R Zarrindast, and F Fatehi, and M Mohagheghi-Badi
January 2013, Avicenna journal of phytomedicine,
M R Zarrindast, and F Fatehi, and M Mohagheghi-Badi
February 2000, Pharmacology, biochemistry, and behavior,
M R Zarrindast, and F Fatehi, and M Mohagheghi-Badi
November 1988, Pharmacology, biochemistry, and behavior,
Copied contents to your clipboard!